Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study
Autore:
Del Dotto, P; Pavese, N; Gambaccini, G; Bernardini, S; Metman, LV; Chase, TN; Bonuccelli, U;
Indirizzi:
Univ Pisa, Dept Neurosci, Neurol Sect, I-56100 Pisa, Italy Univ Pisa Pisa Italy I-56100 Neurosci, Neurol Sect, I-56100 Pisa, Italy NINDS, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA NINDS Bethesda MD USA 20892 Therapeut Branch, NIH, Bethesda, MD 20892 USA
Titolo Testata:
MOVEMENT DISORDERS
fascicolo: 3, volume: 16, anno: 2001,
pagine: 515 - 520
SICI:
0885-3185(200105)16:3<515:IAILDA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEVODOPA-INDUCED DYSKINESIAS; PARKINSONS-DISEASE; ANTAGONIST AMANTADINE; NMDA ANTAGONIST; PHOSPHORYLATION; BLOCKADE; MODEL; BRAIN;
Keywords:
amantadine; levodopa; dyskinesia; Parkinson's disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Bonuccelli, U Univ Pisa, Dept Neurosci, Neurol Sect, Via Roma 67, I-56100 Pisa, Italy Univ Pisa Via Roma 67 Pisa Italy I-56100 -56100 Pisa, Italy
Citazione:
P. Del Dotto et al., "Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study", MOVEMENT D, 16(3), 2001, pp. 515-520

Abstract

Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different: days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous arnantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effectof amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations. (C) 2001 Movement Disorder Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 22:53:31